|
Genetic predisposition to MDS: diagnosis and management |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Lowering the boom on lower-risk myelodysplastic syndromes |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Monitoring and treatment of MDS in genetically susceptible persons |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
|
Young Enough to Undergo Allogeneic Transplantation for Myelodysplastic Syndromes?: Considering the Results of the Medicare Coverage With Evidence Development Study |
Dec 2019 |
JAMA Oncology |
Myelodysplastic Syndromes (MDS) |
|
Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis |
Dec 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party |
Dec 2019 |
Bone Marrow Transplantation |
Aplastic Anemia |
|
Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
Dec 2019 |
Leukemia & Lymphoma |
Aplastic Anemia |
|
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study |
Jan 2020 |
Journal of clinical oncology: official journal of the American Society Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
Jan 2020 |
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
|
Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
Jan 2020 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
